



STATE MEDICAID DUR BOARD MEETING
 THURSDAY, April 12, 2012
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 125



MINUTES

Board Members Present:

Mr. Kumar Shah
 George Hamblin, R.Ph.
 Cris Cowley, M.D.

Tony Dalpiaz, PharmD.
 Joseph Yau, M.D.
 Kathy Goodfellow, R.Ph.

Board Members Excused:

Neal Catalano, R.Ph.
 Mark Balk, PharmD.
 Joseph Miner, M.D.

Brad Hare, M.D.
 Peter Knudson, D.D.S.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD.
 Tim Morley, R.Ph.
 Lisa V Hunt, R.Ph.
 Heather Deering, R.N.

Richard Sorenson, R.N.
 Annette Leonard, R.N.
 Merelynn Berrett, R.N.
 Heather Santacruz, R.N.

Other Individuals Present:

Joanita Lake, UofU
 Chaz Washington, UofU
 Sabrina Aery, BMS

Bryan Larson, UofU
 Brian Hatheway, UofU

Meeting conducted by: Robyn Seely, PharmD.

1. Robyn Seely opened the meeting. She announced that the board chairperson, Neal Catalano is out this month for business reasons.
2. March meeting minutes reviewed and approved with a motion from Joseph Yau. Seconded by Kumar Shah. Approved unanimously.
3. Pharmacy & Therapeutics (P&T) Committee Report: Lisa V. Hunt addressed the Board. They will be reviewing prenatal vitamins for addition to the Preferred Drug List. They will be reviewing sedative hypnotics next month, able to do so due to Senate Bill 85.
4. Review of Black Box Warnings presented by Joanita Lake from the University of Utah. Review included Acitq and other potent opioids prescribed to opiate-naïve patients.

Public comment: none.

Board Discussion: Robyn Seely addressed the board noting that no prior authorization has

been required on these medications in the past, only Nucynta and Nucynta ER require clinical prior authorizations. There are quantity limits on all long acting opioids.

Lisa Hunt reviewed the long acting opioid narcotics that are included on the Preferred Drug List.

The board considered prior authorization requirements on immediate acting fentanyl. Tim Morley asked if any of the short acting transmucosal formulations were indicated for anything other than cancer pain. Joanita Lake responded that the FDA has reviewed this thoroughly and that they do not.

Dr Cris Cowley stated that in the recent years he is seeing more and more patients coming in for surgeries that are using fentanyl patches for non-cancer pain and they are prescribed by non-pain specialists.

Tim Morley asked if they restrict use to cancer patients only then is it necessary to restrict to oncologist prescribed. Lisa Hunt and Robyn Seely reiterated that these are already non-preferred products and therefore require a prior authorization. All of the criteria that the board recommends could be incorporated into one prior authorization (the one that already exists).

The recommended criteria was discussed, whether certain points are stated for safety. The point discussed in most detail was the requirement of oncologist prescribed. Board members discussed if they should keep this requirement for non-cancer pain. Then it was determined that it would be approving off label use. Tim Morley stated that current policy for fentanyl patches less than 100mcg is only restricted for quantity, not diagnosis.

Board Action: Tony Dalpaiz made a motion to only require a cancer diagnosis for transmucosal fentanyl preparations. Cris Cowley seconded the motion. The motion was approved unanimously.

5. Review of current prior authorization criteria presented by Robyn Seely. Review included Increlex, Letaris and Tyvaso.

Public comment: none.

Board Action: A motion was made by Kathy Goodfellow to keep the Increlex criteria the same, no change. Joseph Yau seconded the motion. The motion was approved unanimously.

A motion was made by George Hamblin to remove the clinical prior authorization from Letaris. Tony Dalpiaz seconded the motion. The motion was approved unanimously.

A motion was made by George Hamblin to remove the clinical prior authorization from Tyvaso. Cris Cowley seconded the motion. The motion was approved unanimously.

The next DUR Board meeting is scheduled for Thursday, May 10, 2012.
The DUR Board Prior Approval Subcommittee met following the meeting.
Minutes prepared by Bobbi Hansen.